Vorapaxar

• CAT Number: I004336
• CAS Number: 618385-01-6
• Molecular Formula: C29H33FN2O4
• Molecular Weight: 492.58
• Purity: ≥95%
• Target: Protease Activated Receptor (PAR)
• Solubility: DMSO: ≥ 30 mg/mL
• Storage: 3 years -20C powder
• Related CAS: 705260-08-8(sulfate)

Vorapaxar(CAT: I004336) is a thrombin receptor antagonist that specifically targets the protease-activated receptor 1 (PAR-1). PAR-1 is a receptor found on platelets and other cells involved in blood clotting. By blocking the interaction between thrombin and PAR-1, vorapaxar inhibits platelet activation and aggregation, thereby reducing the risk of thrombotic events. Vorapaxar is primarily used in the prevention of cardiovascular events, such as myocardial infarction and stroke, in patients with a history of atherosclerosis. It is typically prescribed in combination with standard antiplatelet therapy for high-risk individuals.

Reference

1: Wang A. Review of vorapaxar for the prevention of atherothrombotic events.
Expert Opin Pharmacother. 2015;16(16):2509-22. doi:
10.1517/14656566.2015.1099629. Epub 2015 Oct 19. Review. PubMed PMID: 26480240.

2: Poole RM, Elkinson S. Vorapaxar: first global approval. Drugs. 2014
Jul;74(10):1153-63. doi: 10.1007/s40265-014-0252-2. Review. PubMed PMID:
24962425.

3: Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, Mehrhof
F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van de Werf F, Wilcox R, Morrow
DA; TRA 2°P-TIMI 50 Steering Committee Investigators. Vorapaxar for secondary
prevention of thrombotic events for patients with previous myocardial infarction:
a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet. 2012 Oct
13;380(9850):1317-24. doi: 10.1016/S0140-6736(12)61269-0. Epub 2012 Aug 26.
PubMed PMID: 22932716.

4: Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA,
Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux
P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and
Investigators. Vorapaxar in the secondary prevention of atherothrombotic events.
N Engl J Med. 2012 Apr 12;366(15):1404-13. doi: 10.1056/NEJMoa1200933. Epub 2012
Mar 24. PubMed PMID: 22443427.